Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Safeguard Scientifics SFE -- Ignore unavailable to you. Want to Upgrade?

To: michael r potter who wrote (2821)	5/13/1999 12:32:00 PM
From: andy harrison	Read Replies (1) \| Respond to of 4467

Mike: Check out ASTEC INDUSTRIES. ASTE Complete opposite business that SFE is in. Worth the ride.. Sorry about the pun..

To: michael r potter who wrote (2821)	5/13/1999 12:35:00 PM
From: Sir Francis Drake	Read Replies (1) \| Respond to of 4467

Michael - bid 96 3/8 bid right now. In my view, the big resistance is of course 100, so the selling will hit in the 98-99 level, as I see it. Just a question whether you want to squeeze out a few more points or not. There is one additional consideration - if SFE sells off nicely from the high 90's, technically one more wave is possible, as an attempt to break 100. In fact, given the volume we are seeing recently on the way up, it is not impossible that on that second move, it may break 100 and hit 110 before settling down. I've only been trading SFE for a few weeks now, but that's my take on it. Good luck! Morgan

To: michael r potter who wrote (2821)	5/13/1999 4:43:00 PM
From: robert miller	Read Replies (2) \| Respond to of 4467

Michael, I also sold a small amount of SFE today. I took an initial position in FCGI and added to my positions in CVSN and OAOT. When they get FDA approval, I think CVSN will make a nice rally. "The company is awaiting clearance of the 510(k) application filed with the U.S. Food and Drug Administration (FDA) in November of 1998. Dr. Douglas S. Harrington, chief executive officer & president, stated, ''The pending FDA clearance will determine when ChromaVision can aggressively promote and sell the ACIS applications slated for release in 1999. Recent discussions with the FDA were encouraging as no additional data was requested. We do not believe that the duration of the regulatory review will have a material impact on our long-term business plan." bob